GLP-1 Advisor | One Day MD

Scientific Review & Regulatory Audit by the Clinical Editorial Team The therapeutic paradigm for progressive neurodegenerative disorders like Parkinson’s disease (PD) and various forms of dementia faces a critical bottleneck. Standard pharmacology, primarily anchored by levodopa (L-DOPA) for Parkinson’s and acetylcholinesterase inhibitors for dementia, remains strictly symptomatic. These options frequently suffer from diminishing efficacy and significant side-effect profiles like L-DOPA-induced dyskinesia over long-term use. Consequently, the pharmaceutical community has focused heavily on drug repurposing—identifying established, safety-vetted compounds capable of crossing pathways to modify disease progression. An unexpected frontline candidate emerging in this space is ivermectin. Traditionally classified as a broad-spectrum antiparasitic agent, a surge of preclinical studies between 2020 and 2024 has unveiled its complex, multi-targeted pharmacodynamics within the mam...

Abstract Dengue virus infection lacks a specific approved antiviral. Supportive care remains the standard of management. This 2026 narrative review synthesizes evidence on repurposed agents, with detailed analysis of ivermectin (clinical trials and scarce case reports) and vitamin D (observational associations with severity, supplementation trials, and immunomodulatory mechanisms). While ivermectin accelerates NS1 clearance without proven clinical benefit, vitamin D deficiency correlates with increased severity in multiple studies, and high-dose supplementation has shown signals of reduced progression to severe dengue in small randomized trials. Emerging candidates such as mosnodenvir, VIS-513 monoclonal antibody, and EYU688 offer stronger developmental promise. Vitamin D represents a safe, inexpensive adjunctive option warranting larger confirmatory trials. Keywords: ivermectin dengue treatment, vitamin D dengue, d...